Natco Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2025
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma held its 42nd Annual General Meeting on September 25, 2025, where all 8 resolutions were passed with overwhelming shareholder support. Promoters (holding 8.87 crore shares) voted 100% in favour, while institutional holders showed strong backing. Key resolutions included adoption of FY25 audited financials, confirmation of three interim dividends totalling Rs. 6 per share as the final dividend, re-appointment of Director Rajeev Nannapaneni, and approval of enhanced borrowing powers. A special resolution to increase the company's authorized share capital was also passed, with 99.99% approval. Overall, 1.16 crore votes were polled (about 64.7% of total shares), with nearly 100% in favour across all items.
All resolutions passed comfortably, showing strong promoter and institutional confidence with no meaningful dissent. The share capital increase resolution gives the company room for future fundraising or stock splits, while the confirmed Rs. 6 per share total dividend reinforces its shareholder-friendly payout track record. No negative impact expected on the stock.